Hazuki Nakai1, Mao Hagihara2, Hideo Kato2, Jun Hirai1, Naoya Nishiyama3, Yusuke Koizumi3, Daisuke Sakanashi3, Hiroyuki Suematsu3, Yuka Yamagishi3, Hiroshige Mikamo4. 1. Department of Clinical Infectious Diseases, Aichi Medical University Graduate School of Medicine, Japan. 2. Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Pharmacy, Aichi Medical University Hospital, Japan. 3. Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan. 4. Department of Clinical Infectious Diseases, Aichi Medical University Graduate School of Medicine, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan. Electronic address: mikamo@aichi-med-u.ac.jp.
Abstract
OBJECTIVE: To study the clinical characteristics and associated risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. METHODS: A case-control study at a large university hospital in Japan, comparing patients who were infected or colonized with ESBL-producing Enterobacteriaceae (n = 212) and non-ESBL-producing Enterobacteriaceae (n = 2089) in 2010-2013. Data were collected from medical charts, retrospectively. Multivariate logistic regression analysis was used to explore risk factors of ESBL-producing Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis) infection or colonization for each pathogen, respectively. RESULTS: ESBL-producing Enterobacteriaceae [E. coli (n = 113), K. oxytoca (n = 46), K. pneumoniae (n = 41), P. mirabilis (n = 12)] were taken from patients were identified in 1409 outpatient and 892 inpatients. Infection or colonization caused by ESBL-producing Enterobacteriaceae was considered to be hospital-acquired, healthcare-associated and community-acquired in 60.4%, 17.9% and 21.7% patients, respectively. Independent risk factors for ESBL-producing Enterobacteriaceae infection or colonization were male sex, cerebrovascular disease, intubation/tracheostomy, major surgery within 60 days (p < 0.001). Moreover, antimicrobial usage (more than 4 days) during preceding 60 days, especially aminoglycoside, oxazolidinone, tetracycline, fluoroquinolone, trimethoprim/sulfamethoxazole, and second- and fourth-generation cephalosporin were risk factors (p < 0.001). However, acquisition location of infection (hospital-acquired and community-onset) was not a risk factor (p > 0.05). CONCLUSION: The problem of ESBL production is no longer limited to hospital-acquired infections. The presence of chronic illness, such as cerebrovascular disease, and recent antimicrobial use were independent risk factors for ESBL-producing Enterobacteriaceae infection or colonization.
OBJECTIVE: To study the clinical characteristics and associated risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. METHODS: A case-control study at a large university hospital in Japan, comparing patients who were infected or colonized with ESBL-producing Enterobacteriaceae (n = 212) and non-ESBL-producing Enterobacteriaceae (n = 2089) in 2010-2013. Data were collected from medical charts, retrospectively. Multivariate logistic regression analysis was used to explore risk factors of ESBL-producing Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis) infection or colonization for each pathogen, respectively. RESULTS:ESBL-producing Enterobacteriaceae [E. coli (n = 113), K. oxytoca (n = 46), K. pneumoniae (n = 41), P. mirabilis (n = 12)] were taken from patients were identified in 1409 outpatient and 892 inpatients. Infection or colonization caused by ESBL-producing Enterobacteriaceae was considered to be hospital-acquired, healthcare-associated and community-acquired in 60.4%, 17.9% and 21.7% patients, respectively. Independent risk factors for ESBL-producing Enterobacteriaceae infection or colonization were male sex, cerebrovascular disease, intubation/tracheostomy, major surgery within 60 days (p < 0.001). Moreover, antimicrobial usage (more than 4 days) during preceding 60 days, especially aminoglycoside, oxazolidinone, tetracycline, fluoroquinolone, trimethoprim/sulfamethoxazole, and second- and fourth-generation cephalosporin were risk factors (p < 0.001). However, acquisition location of infection (hospital-acquired and community-onset) was not a risk factor (p > 0.05). CONCLUSION: The problem of ESBL production is no longer limited to hospital-acquired infections. The presence of chronic illness, such as cerebrovascular disease, and recent antimicrobial use were independent risk factors for ESBL-producing Enterobacteriaceae infection or colonization.
Authors: Sin Young Ham; Hyungul Jung; Kyoung-Ho Song; Hyeonju Jeong; Jongtak Jung; Song Mi Moon; Jeong Su Park; Nak-Hyun Kim; Eun Sun Jang; Jin-Wook Kim; Sook-Hyang Jeong; Eu Suk Kim; Hong Bin Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2022-10-13 Impact factor: 5.103
Authors: Judith A Anesi; Ebbing Lautenbach; Pranita D Tamma; Kerri A Thom; Emily A Blumberg; Kevin Alby; Warren B Bilker; Alissa Werzen; Pam Tolomeo; Jacqueline Omorogbe; Lisa Pineles; Jennifer H Han Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079
Authors: Philipp Kohler; Rosamaria Fulchini; Werner C Albrich; Adrian Egli; Carlo Balmelli; Stephan Harbarth; Delphine Héquet; Christian R Kahlert; Stefan P Kuster; Christiane Petignat; Matthias Schlegel; Andreas Kronenberg Journal: Antimicrob Resist Infect Control Date: 2018-07-20 Impact factor: 4.887